ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In vivo treatment of Scl-tTa-BCR-ABL mice with LDE225 ± nilotinib resulted in inhibition of Gli1 in CP-CML BM LTHSC (Fig. 3A).